The board of directors of Pfizer Inc (NYSE:PFE) declared on Thursday its dividend of USD0.34 on its common stock for the Q4 2018.
Shareholders of record at the close of business on 9 November 2018 will receive the dividend payment on 3 December 2018.
In addition, the cash dividend will be the company's 320th consecutive quarterly dividend.
According to the company, it is engaged in the discovery, development and manufacture of health care products, including medicines and vaccines as well as many of the world's best-known consumer health care products.
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV